Publications by authors named "Prof Morihito Okada"
Article Synopsis
- The NEJ026 Phase 3 study found that combining erlotinib and bevacizumab (BE) improved progression-free survival (PFS) in NSCLC patients with EGFR mutations compared to erlotinib alone.
- Plasma samples were analyzed to assess the relationship between circulating tumor DNA (ctDNA) mutations and treatment efficacy, with findings indicating that 68% had detectable activating EGFR mutations at the start of treatment.
- Results showed that patients without these mutations had longer PFS, and the combination therapy (BE) consistently outperformed erlotinib alone in various patient response profiles.
